AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Association of Testosterone-to-Estradiol Ratio with Inflammation and Clinical Outcomes Among Postmenopausal HFpEF

By Qi M, Sun R, Wang W et al.

Objective: Sex hormone may contribute to the inflammatory and diastolic dysfunction of heart failure with preserved ejection fraction (HFpEF) in women, but data on the testosterone-to-estradiol ratio (T/E2) are limited. We investigated whether the T/E2 is associated with systemic inflammation, diastolic dysfunction, and short-term outcomes in postmenopausal women with HFpEF. Methods: In the single-center prospective cohort, we recruited 184 postmenopausal women with HFpEF and followed up for 12 months. Baseline total testosterone and estradiol were measured by radioimmunoassay. Systemic inflammation was assessed by hs-CRP, IL-6, neutrophil-to-lymphocyte ratio (NLR) and D-dimer. Spearman correlations and multivariable linear regression were performed to evaluate the associations between T/E2 and systemic inflammation and diastolic parameters. Associations of baseline T/E2 with 12-month NT-proBNP were examined using ANCOVA with adjustment for baseline NT-proBNP, and associations with major adverse cardiovascular events (MACE) were examined using multivariable logistic regression. Results: Median testosterone and estradiol concentrations were 14.61 ng/dL and 18.52 pg/mL, respectively. T/E2 was negatively associated with hs-CRP, NLR, IL-6, and E/e′. In multivariable linear regression analyses, lower T/E2 remained independently associated with higher hs-CRP, NLR, IL-6 and E/e’. BMI and years since menopause significantly modified the relationships of T/E2 with hs-CRP and E/e’. Additionally, baseline T/E2 was not associated with 12-month NT-proBNP (β=0.114, P=0.212), but was associated with lower odds of 12-month MACE (OR=0.678, P=0.037). Conclusions: In postmenopausal women with HFpEF, lower T/E2 is associated with greater systemic inflammation, worse diastolic hemodynamics, and higher short-term event risk, with heterogeneity by adiposity and menopausal duration.

doi.org/10.1161/circ.154.suppl_1.7909Biomarkers

AgingResearch.News